⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
ASO Therapy Targeting LMNA/Progerin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.: Preclinical mouse study: AI-designed ASO LM2556 targeting LMNA 3’UTR selectively lowered progerin and farnesylated pre-lamin A (sparing lamin C), rescued cardiovascular pathology, and extended median lifespan by ~82.86% in progeroid LMNA transgenic mice with no reported hepato- or nephrotoxicity. [animal-model] (novelty: 4)
Open questions
Related
Contributing findings
AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.
01-jul-2026
novelty 4
per-area 4
strengthens